Shanghai HeartCare Medical Technology (HKG:6609) plans to extend the validity period for its 2022 A share issue and its relevant authorization for another year, a Thursday Hong Kong bourse filing said.
The validity period for the issue will expire on Nov. 7, 2024, and as the proceedings for the issue are still ongoing, the company plans to extend the period for another 12 months.
The neuro-interventional medical devices manufacturer's shares closed over 1% lower on Thursday.
Price (HKD): $19.76, Change: $-0.24, Percent Change: -1.20%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.